Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

KEYPOINTS

• 01

  Depression is an umbrella, and among the most disabling conditions worldwide

  Williams, a Stanford psychiatrist also trained in neurology, says depression ranges from anxious and overactive to flat and unmotivated. His lab works with Conor Liston's group at Cornell to define biotypes from brain imaging. He compares moderate depression to the disability of an acute heart attack and severe depression to that of untreated, terminal cancer. The American Heart Association now lists depression as a fourth major risk factor for coronary artery disease.

• 02

  Psychiatry has fewer tools as a case gets more acute

  In cardiology, an emergency room or ICU offers more tests and treatments than a clinic. In psychiatry, someone who moves from depressed to suicidal often gets the same oral antidepressants they were already taking. Williams' work targets this emergency gap.

• 03

  The prefrontal cortex is wired to the heart

  TMS uses a magnetic pulse to induce current in brain tissue only. Stimulating the left dorsolateral prefrontal cortex (DLPFC) spreads through the cingulate, insula and amygdala to the nucleus tractus solitarius and the vagus nerve, briefly slowing the heart. Williams stresses that the slowing marks that you have hit the right network; it is not itself the treatment. Simply lowering heart rate, for instance with a beta blocker, is unlikely to treat depression.

• 04

  There is a 'volitional threshold' in depression

  In mild depression, small but well-designed studies support meditation, mindfulness and exercise, and low heart-rate variability is associated with moderate to severe depression. As depression deepens, thoughts become only partly under voluntary control, so behavioral tools work less well. The extreme end is catatonia.

• 05

  Ketamine's antidepressant effect appears to need the opioid system

  In Williams' crossover trial, the same patients received standard ketamine with either 50 mg naltrexone or a placebo. Naltrexone largely blocked the antidepressant effect, yet the dissociative 'trip' felt identical. He takes this to mean that pharmacology, not just the subjective experience, matters. He notes that opioids may relieve emotional pain short term but are pro-depressant chronically.

• 06

  MDMA's neurotoxicity reputation rests partly on a mistake

  Huberman recounts that an influential Science paper reporting serotonin-neuron damage had in fact injected methamphetamine, as the same group later acknowledged. Williams cites a NIDA-funded study of MDMA-only users in Utah's LDS community that found no neurocognitive differences, plus pre/post testing from early MDMA trials. He concludes there is no apparent risk at one to three clinical doses, with purity assured. Huberman adds that the post-MDMA slump may reflect a prolactin rebound after the dopamine surge.

• 07

  Psilocybin and targeted TMS converge on one circuit

  Imaging by David Nutt and Robin Carhart-Harris found overall brain activity decreases on psychedelics while global connectivity increases. Williams says the antidepressant effect of psilocybin, like his TMS protocol, reduces connectivity between the subgenual anterior cingulate (negative mood) and the default mode network (self-representation).

• 08

  Ibogaine produces a 'life review', with cardiac risk

  Ibogaine comes from the root bark of an iboga shrub used sacramentally by the Bwiti in Gabon. It produces few open-eye visuals; with eyes closed, people replay past memories with detached empathy, sometimes for 24–36 hours. Williams calls it seemingly the most powerful psychedelic, but also the riskiest, because of cardiac effects his team screened for with ECGs. It is not recreational.

• 09

  Stanford Neuromodulation Therapy (SNT) applies spaced learning to TMS

  Standard TMS runs once daily for six weeks. SNT gives 10 sessions a day, an hour apart, for five days: about 90 minutes of total stimulation, roughly five times the usual dose. It uses theta-burst pulses that mimic hippocampal rhythms and are aimed via each person's own connectivity scan. Williams reports remission in 60–90% of cases depending on the study, often within days, though durability varies (some patients a year, some four).